Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$61.4MCash, Jun 2026
26moCash Runway (est.)
+58%Share Count, 1 Year
Follow UNCY by emailGet an email when UNCY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about UNCY, unsubscribe in one click. Privacy
📣 What UNCY Says Is Next
second half of 2027 · “As of June 30, 2026, unaudited cash, cash equivalents and marketable securities totaled $61.4 million, supporting continued OLC commercial launch preparation and an expected cash runway into the second half of 2027.”
Company press release, Sep 29, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
UNCY reported $61.4M in cash and short-term investments (as of Jun 30, 2026) and used about $7M/quarter in operations, an estimated runway of 26.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:45 · Elevated
Cash runway 26 months
ATM program on file since Jun 2026 +15
Shelf registration (S-3, Jun 2026) +10
Share count +58% in a year +20
Recent financing filings on SEC EDGAR:
Jun 5, 2026 · Shelf registration with ATM program, up to $50M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UNCY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.